Evidence map›Paper›PMID 42496568›Full record

ArticleBiotech (Basel (Switzerland))2026

Global Patent Landscape and Technological Trends in Biosafety Level 3 (BSL-3) Laboratories Technologies.

Milca de J Silva, Roni D Vinhas, Helena S da Hora, Saada L C Fernandez, Hayna Malta-Santos, Hugo Saba, Camila D F Ribeiro, Marilda de S Gonçalves, Bruna A S Machado

Abstract read
In one paragraph

Article in Biotech (Basel (Switzerland)), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Milca de J SilvaSENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), SENAI CIMATEC University, SENAI CIMATEC, Salvador 41650-010, BA, Brazil.
Roni D VinhasPostgraduate Program in Industrial Management and Technology, SENAI CIMATEC University, SENAI CIMATEC, Salvador 41650-010, BA, Brazil.
Helena S da HoraSENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), SENAI CIMATEC University, SENAI CIMATEC, Salvador 41650-010, BA, Brazil.
Saada L C FernandezOswaldo Cruz Foundation-Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil.ORCID 0009-0000-5867-6175
Hayna Malta-SantosSENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), SENAI CIMATEC University, SENAI CIMATEC, Salvador 41650-010, BA, Brazil.ORCID 0000-0003-3987-5392
Hugo SabaDepartment of Exact and Earth Sciences, State University, Salvador 41150-000, BA, Brazil.ORCID 0000-0001-8402-6416
Camila D F RibeiroNutrition School, Federal University of Bahia, Salvador 40110-907, BA, Brazil.ORCID 0000-0003-2968-5739
Marilda de S GonçalvesGonçalo Moniz Institute, Oswaldo Cruz Foundation-Fiocruz, Salvador 40296-710, BA, Brazil.
Bruna A S MachadoSENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), SENAI CIMATEC University, SENAI CIMATEC, Salvador 41650-010, BA, Brazil.

Funding

Fundação de Amparo à Pesquisa do Estado da Bahia DCR0013/2024
6 · The paper itself

Abstract

Biosafety Level 3 (BSL-3) laboratories are essential for handling high-risk pathogens and strengthening global health security. This study presents a patent landscape analysis of BSL-3-related technologies using the Derwent World Patents Index (DWPI) to identify technological trends, geographic distribution, patent classifications, and temporal evolution. Patent documents associated with laboratory infrastructure, ventilation systems, containment devices, and biosafety procedures were screened and analyzed. A total of 58 patent documents filed between 2009 and 2024 met the inclusion criteria. The results showed that China and the United States are the leading contributors to BSL-3 patent development, reflecting continued investments in biosafety and biosecurity infrastructure. The most frequent International Patent Classification (IPC) categories were C12M (microbiological devices), E04H (specialized construction infrastructure), and F24F (ventilation and air control systems), highlighting the multidisciplinary nature of innovations in laboratory containment and safety. The temporal trends revealed increases in patent activity following major public health emergencies, including SARS, Ebola, and particularly the COVID-19 pandemic. Furthermore, a significant increase in patent expirations is expected by 2029, creating opportunities for technology transfer, open innovation, and broader access to critical biosafety technologies. These findings emphasize the strategic importance of continued investment in BSL-3 technologies, especially in developing countries with growing biosafety demands.

Indexed as

biosafety technologiesBSL-3 laboratoriespatent analysis

Identifiers

PMID42496568
PMCPMC13397928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.